Dyne Therapeutics (DYN) presented at JPM yesterday. Find a recap below.

Dyne (DYN) just laid out a massive roadmap at JPM, and the main takeaway is that they are officially shifting from a R&D story to a commercial powerhouse. John Cox, Dyne’s CEO, led the presentation and he seems to be the right person for this transition. He’s a veteran in the space who has launched multiple rare disease drugs throughout his career. He spoke with a lot of confidence about their $1 billion cash cushion and the fact that they wholly own these assets.  Cox highlighted that Dyne has Breakthrough Designation for both their DMD and DM1 programs, which has opened up a "routine, bidirectional, and positive" dialogue with regulators. The FDA has remained consistent in its feedback: they are open to Accelerated Approval based on the data Dyne is putting up. On the clinical side, the numbers are promising. Their DMD candidate is showing 10x higher dystrophin levels than the current standard of care, and their DM1 program saw a 20% increase in muscle strength at the 12-month mark. It’s relatively rare to find a biotech with two late-stage assets this de-risked and a veteran CEO who has extensive experience with commercialization strategy. The 2026-2027 Roadmap: • Q2 2026: Submit BLA (regulatory filing) for Z-Rostudirsen in DMD.  • Q2 2026: Launch the Phase 3 confirmatory trial for DMD. • Early Q2 2026: Finish enrolling the 60-patient registration cohort for DM1. • Q1 2027: Targeted commercial launch for the DMD program. • Q1 2027: Read out the registrational data for DM1. • 2028: Planned commercial launch for the DM1 program. • Ongoing 2026: Move FSHD into the clinic as the next major pipeline expansion.